Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond

Bibliography

• Ensinger C, Sterlacci W. Implications of EGFR PharmDx kit for cetuximab eligibility. Expert Rev Mol Diagn 2008;8(2):141-8
   PubMed Web of Science ®Google Scholar
• Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol 2010;22(6):586-91
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Gong Y, Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008;112(9):1905-11
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kang Y, Chung H, Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009;27(18s): abstract 4509
   Google Scholar
• Ruschoff J, Dietel M, Baretton G, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457(3):299-307
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94(5):1593-611
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37(Suppl 4):9-15
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):3-8
   PubMedGoogle Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Juan T, Reiner M, Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008;7(3):184-90
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, Folprecht G, Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol 2010;28(15s): abstract 3570
   Google Scholar
• Siena S, Tabernero J, Cunningham D, Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. J Clin Oncol 2010;28(15s): abstract 3566
   Google Scholar
• Sharma SV, Bell DW, Settleman J, Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Inoue A, Kobayashi K, Usui K, First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27(9):1394-400, Erratum in: J Clin Oncol 2009;27(18):3071
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Maemondo M, Okinaga S, First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study). J Clin Oncol 2010;28(15s): abstract 7561
   Google Scholar
• Rosell R, Moran T, Queralt C, Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361(10):958-67
   PubMed Web of Science ®Google Scholar
• Bang Y, Kwak EL, Shaw AT, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15s): abstract 3
   Google Scholar
• Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov Today 2005;10(11):781-8
   PubMed Web of Science ®Google Scholar